Valiant Laboratories files Regulation 74(5) Certificate for Q2 FY26
Valiant Laboratories submitted its Regulation 74(5) certificate for Q2 FY26, confirming all securities are dematerialized and no requests for physical share processing were received.
This is a mandatory regulatory filing with no material business or financial implications, indicating standard operational compliance without any new significant events.
The announcement is a routine compliance filing confirming adherence to SEBI regulations regarding dematerialized securities and lack of physical share transfer requests, which is a standard operational update.
Valiant Laboratories Limited has submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025. * The certificate was received from MUFG Intime India Private Limited, the Company's Registrar and Share Transfer Agent. * It confirms that Regulation 74(5) is not applicable to Valiant Laboratories Limited. * All of the Company's securities are held in dematerialized form. * No requests for dematerialization, mutilation, or cancellation of securities were received by the Company, its RTA, or Depository Participants during the quarter ended September 30, 2025.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.